Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate

Lone, Zaeem; Benidir, Tarik; Rainey, Magdalena A.; Nair, Monica; Davicioni, Elai; Gibb, Ewan A.; Williamson, Sean R.; Gupta, Shilpa; Ornstein, Moshe Chaim; Tendulkar, Rahul D.; Weight, Christopher J.; Nguyen, Jane; Klein, Eric A.; Mian, Omar Y.

doi:10.1016/j.euf.2022.05.005

Cited by 10 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 This phenomenon results in the loss of critical tumor suppressor genes, including TP53, RB1, and PTEN, while also leading to the overexpression of oncogenes such as MYC. [2][3][4][5][6][9][10][11] TP53 and RB1 play critical roles in controlling cell cycle progression, with TP53 acting as a central hub for DNA damage response pathways. 51 RB1 primarily regulates the G1 to S transition during the cell cycle, 52 which is carried out by binding to and inhibiting the activity of the E2F family of transcription factors.…”

Section: Tp53 Rb1 Pten and Mycmentioning

confidence: 99%

“…Therefore, it is not surprising that IDC-P exhibits enriched pathways associated with E2F targets. 9 In addition, TP53, RB1, and MYC have been implicated in the development of neuroendocrine prostate cancer (NEPC), a subtype characterized by poor prognosis and resistance to standard treatments. 53,54 TP53 and RB1 have been reported to regulate the differentiation of T A B L E 1 Summary of the important molecular findings on intraductal carcinoma of the prostate (IDC-P).…”

Section: Tp53 Rb1 Pten and Mycmentioning

confidence: 99%

“…RB1 primarily regulates the G1 to S transition during the cell cycle, 52 which is carried out by binding to and inhibiting the activity of the E2F family of transcription factors. Therefore, it is not surprising that IDC‐P exhibits enriched pathways associated with E2F targets 9 …”

Section: Tp53 Rb1 Pten and Mycmentioning

confidence: 99%

See 2 more Smart Citations

Molecular complexity of intraductal carcinoma of the prostate

Zhu,

Xu,

Zeng

2024

Cancer Medicine

View full text Add to dashboard Cite

Intraductal carcinoma of the prostate (IDC‐P) is an aggressive subtype of prostate cancer characterized by the growth of tumor cells within the prostate ducts. It is often found alongside invasive carcinoma and is associated with poor prognosis. Understanding the molecular mechanisms driving IDC‐P is crucial for improved diagnosis, prognosis, and treatment strategies. This review summarizes the molecular characteristics of IDC‐P and their prognostic indications, comparing them to conventional prostate acinar adenocarcinoma, to gain insights into its unique behavior and identify potential therapeutic targets.

show abstract

Section: Tp53 Rb1 Pten and Mycmentioning

confidence: 99%

Section: Tp53 Rb1 Pten and Mycmentioning

confidence: 99%

See 1 more Smart Citation

Molecular complexity of intraductal carcinoma of the prostate

Zhu,

Xu,

Zeng

2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…It is time taking test with a limitation to require 10 year or more to complete. [22,23] There are a number of prognostic tests available for commercial gene expression signatures. These subsets of biomarkers assist clinicians in discriminating against aggressive vs. indolent prostate tumors.…”

Section: Prognostic Biomarkers and Their Limitations In Prostate Cancermentioning

confidence: 99%

Aquaporins as Prognostic Biomarker in Prostate Cancer

Kushwaha

Verma

Gupta

2023

Cancers

View full text Add to dashboard Cite

Prostate cancer is a complex heterogeneous disease that affects millions of males worldwide. Despite rapid advances in molecular biology and innovation in technology, few biomarkers have been forthcoming in prostate cancer. The currently available biomarkers for the prognosis of prostate cancer are inadequate and face challenges, thus having limited clinical utility. To date, there are a number of prognostic and predictive biomarkers identified for prostate cancer but lack specificity and sensitivity to guide clinical decision making. There is still tremendous scope for specific biomarkers to understand the natural history and complex biology of this heterogeneous disease, and to identify early treatment responses. Accumulative studies indicate that aquaporins (AQPs) a family of membrane water channels may serve as a prognostic biomarker for prostate cancer in monitoring disease advancement. In the present review, we discuss the existing prostate cancer biomarkers, their limitations, and aquaporins as a prospective biomarker of prognostic significance in prostate cancer.

show abstract

“…Zaeem et al identified predictors of high-risk Decipher scores (>0.60) for index lesions from RP specimens from 463 patients. 83 Decipher evaluates the entire transcriptome of prostate cancer specimens and determines a risk score based on a clinically validated 22-gene signature. 84,85 IDC-P/CApositive patients had higher risk scores for Decipher compared to IDC-P/CA-negative patients.…”

Section: Dna Damage Repair Gene Mutationsmentioning

confidence: 99%

Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate

Naito,

Kato,

Nagayama

et al. 2023

Int J of Urology

View full text Add to dashboard Cite

Intraductal carcinoma of the prostate, a unique histopathologic entity that is often observed (especially in advanced prostate cancer), is characterized by the proliferation of malignant cells within normal acini or ducts surrounded by a basement membrane. Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high‐grade carcinoma and is occasionally observed as an isolated subtype. Intraductal carcinoma of the prostate has been demonstrated to be an independent poor prognostic factor for all stages of cancer, whether localized, de novo metastatic, or castration‐resistant. It also has a characteristic genetic profile, including high genomic instability. Recognizing and differentiating it from other pathologies is therefore important in patient management, and morphological diagnostic criteria for intraductal carcinoma of the prostate have been established. This review summarizes and outlines the clinical and pathological features, differential diagnosis, molecular aspects, and management of intraductal carcinoma of the prostate, as described in previous studies. We also present a discussion and future perspectives regarding intraductal carcinoma of the prostate.

show abstract

Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate

Cited by 10 publications

References 30 publications

Molecular complexity of intraductal carcinoma of the prostate

Molecular complexity of intraductal carcinoma of the prostate

Aquaporins as Prognostic Biomarker in Prostate Cancer

Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate

Contact Info

Product

Resources

About